Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2012; 18(16): 1915-1920
Published online Apr 28, 2012. doi: 10.3748/wjg.v18.i16.1915
Published online Apr 28, 2012. doi: 10.3748/wjg.v18.i16.1915
Table 1 Patient demographics n (%)
Neoadjuvant chemotherapy group | Primary surgery group | |
Total number of patients | 97 | 122 |
Median age (yr) | 64 | 74.5 |
Sex | ||
Male | 74 (76) | 92 (75.4) |
Female | 23 (24) | 30 (24.6) |
T stage | ||
T1 | 6 (6.1) | 12 (9.8) |
T2 | 29 (29.8) | 41 (33.6) |
T3 | 50 (51.5) | 65 (53.2) |
T4 | 8 (8.2) | 4 (3.2) |
TX | 1 (1) | |
N stage | ||
N0 | 31 (31.9) | 32 (26.2) |
≥ N1 | 66 (68.1) | 90 (73.8) |
M stage | ||
M0 | 97 (100) | 122 (100) |
M1 | - | - |
Tumour type | ||
Adenocarcinoma | 83 (85.5) | 122 (100) |
Squamous cell carcinoma | 12 (12.3) | - |
Adenosquamous | 2 (2) | - |
Site of tumour | ||
Gastric | 20 (20.6) | 122 (100) |
GOJ | 47 (48.4) | - |
Lower third of oesophagus | 36 (37.1) | - |
Surgery | ||
Total gastrectomy | 22 | 70 |
Partial gastrectomy | 5 | 39 |
Oesophagectomy/ Oesophago-gastrectomy | 70 | 13 |
Survival status | ||
Alive | 47 (48.4) | 47 (38) |
Dead | 50 (51.6) | 75 (62) |
Table 2 Caspase-cleaved cytokeratin-18 and tumour regression in tumours exposed to neoadjuvant chemotherapy n (%)
Caspase-cleaved CK-18 | TRG1, TRG2, TRG3 | TRG4, TRG5 | Total |
Negative | 10 (23.8) | 32 (76.2) | 42 (100) |
Positive | 24 (43.6) | 31 (56.4) | 55 (100) |
Total | 34 (35.1) | 63 (64.9) | 97 (100) |
Table 3 Univariate and multivariate analyses showing predictive factors for disease-specific and overall survival in neoadjuvant and surgery only groups
Univariate analysis | Multivariate analysis | ||
DSS | OS | OS | |
Neoadjuvant group | |||
Caspase-cleaved CK-18 positivity | 0.975 | 0.865 | 1.32 |
TRG 1-3 vs 4-5 | 0.038 | 0.136 | 0.109 |
Tumour diff. (well/mod vs poor) | 0.087 | 0.101 | 0.32 |
T stage (T1, 2 and 3, 4) | 0.07 | 0.09 | 0.101 |
N stage (N0 and > N1) | 0.106 | 0.124 | 0.23 |
M stage (M0 and > M0) | 0.23 | 0.14 | 1.72 |
Vascular invasion | 0.87 | 0.76 | 0.86 |
Perineural invasion | 1.32 | 1.455 | 1.76 |
Resection margin involvement | 2.34 | 1.98 | 0.24 |
Surgery only group | |||
Caspase-cleaved CK-18 positivity | 0.003 | 0.668 | 0.10 |
TRG 1-3 vs 4-5 | 0.87 | 0.003 | 0.23 |
Tumour diff. (well/mod vs poor) | 0.39 | 0.34 | 0.21 |
T stage (T1, 2 and 3, 4) | 0.04 | 0.08 | 0.19 |
N stage (N0 and > N1) | 0.16 | 0.10 | 0.43 |
M stage (M0 and > M0) | 1.27 | 1.64 | 1.99 |
Vascular invasion | 1.98 | 1.67 | 1.34 |
Perineural invasion | 1.56 | 1.99 | 2.43 |
Resection margin involvement | 0.34 | 0.25 | 0.34 |
- Citation: Fareed KR, Soomro IN, Hameed K, Arora A, Lobo DN, Parsons SL, Madhusudan S. Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy. World J Gastroenterol 2012; 18(16): 1915-1920
- URL: https://www.wjgnet.com/1007-9327/full/v18/i16/1915.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i16.1915